SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS

SBIR 主题 294 第一阶段 - 糖基化特异性研究试剂的开发

• 批准号: 8353832
• 负责人: MARIA HINES
• 金额: $ 15万
• 依托单位: GLYCOSCIENTIFIC, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2012-06-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8353832
• 关键词: Animals; Antibodies; Antigens; Contracts; Detection; Development; Epitopes; Glycopeptides; Government; Harvest; Hybridomas; Immunization; Immunoassay; Injectable; Libraries; Malignant Neoplasms; Measurement; Modification; Monoclonal Antibodies; Mus; Phase; Polysaccharides; Preparation; Production; Proteins; Reagent; Reporting; Research; Role; Screening procedure; Site; Small Business Innovation Research Grant; Specificity; Synthetic Antigens; Synthetic Vaccines; Western Blotting; Work; candidate selection; glycosylation; hybridoma production; peptide structure; programs; protein aminoacid sequence; response; tumorigenesis

This statement of work concerns a contract for the proposed effort ¿Production of Site‐Specific O‐GlcNAc Antibodies¿ in response to Small Business Innovation Research (SBIR) Program PHS2011‐1. The project seeks to produce monoclonal antibodies (MAbs) to three selected cancer‐related protein targets, and more specifically, MAbs that will that will permit detection of the presence of the specific glycosylation within these protein target sites by the O‐GlcNAc moiety. For each of the three (3) selected proteins, a synthetic ¿tripartite¿ immunogen will be synthesized, animals will be immunized to conjugates of this synthetic antigen, and a large number of hybridoma cultures will be produced to be screened for specific interactions. An increasingly stringent regime of immunoassays will be employed to define the specificity and reactivity of the MAbs towards producing reagents that will permit detection of the modification of the particular protein sites by O‐GlcNAc. The provision of specific reagents that allow detection of the O‐GlcNAc modification of the specific sites in these specific proteins will define the utility of the ¿tripartite¿ immunogen approach, as well as supply reagents that will aid in elucidating the role of O‐GlcNAc modification in cellular control circuits, including that those that may involve these specific proteins in oncogenesis.

本工作说明书涉及一份合同，该合同拟用于生产位点特异性O GlcNAc抗体， 响应小企业创新研究（SBIR）计划PHS2011 1。该项目旨在生产单克隆 针对三种选定的癌症相关蛋白质靶标的单克隆抗体（MAb），更具体地，将允许 通过OGlcNAc部分检测这些蛋白质靶位点内特异性糖基化的存在。为每个 在三（3）种选定的蛋白质中，将合成一种合成的三联免疫原，动物将被免疫， 这种合成抗原的偶联物，并且将产生大量杂交瘤培养物以进行筛选。 具体互动。将采用越来越严格的免疫测定方案来确定特异性和 MAb对产生允许检测特定蛋白质修饰的试剂的反应性 网站由O GlcNAc.提供允许检测特异性寡核苷酸的OGlcNAc修饰的特异性试剂， 这些特异性蛋白质中的位点将确定三方免疫原方法的效用，以及供应试剂 这将有助于阐明OGlcNAc修饰在细胞控制回路中的作用，包括那些可能 在肿瘤发生中涉及这些特异性蛋白质。